Kidney cancer at ASCO GU: PAPMET & CLEAR

20 vistas

TAKE ACTION

Donations would go to support charities for Cómo hacer y estilo

En Cómo hacer y estilo

Jeffrey Graham, MD, University of Manitoba, Winnipeg, Canada, describes some of the most exciting kidney cancer research presented at ASCO GU 2021. The Phase II PAPMET study (NCT02761057) demonstrated that cabozantinib resulted in a significant improvement in progression-free survival in metastatic papillary renal cell carcinoma (pRCC), compared to sunitinib. Dr. Graham also provides an overview of the Phase 3 CLEAR trial (NCT02811861), which evaluated first-line sunitinib monotherapy compared to lenvatinib plus pembrolizumab or everolimus in patients with advanced RCC. This interview took place during the 2021 Genitourinary Cancers Symposium.

More ways to take action

Explore ways that you can help bring a solution to this issue.

Create Youms with
hashtags Cómo hacer y estilo

Create a challenge to
bring awareness to this issue for people to complete

Create a fundraiser to
support a charity that tackle this issue

Volunteer at charitable organization
that support this cause

Create a movement page dedicated to this cause to bring awareness.

Start a uCharity for this cause and invite people to join it to support this cause

Hasta la próxima

Auto reproducción

Maui wildfire death toll mounts as devastation becomes clear

uchetex · 6 vistas

Tenga en cuenta que si es menor de 18 años, no podrá acceder a este sitio.

Hasta la próxima

Kidney cancer at ASCO GU: PAPMET & CLEAR

Hasta la próxima

Categorías

Elija un método de pago